about
Mu-opioid antagonists for opioid-induced bowel dysfunctionOpioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individualsOpioid-induced constipation: advances and clinical guidanceEvolving paradigms in the treatment of opioid-induced bowel dysfunctionClinical potential of naloxegol in the management of opioid-induced bowel dysfunctionEmerging therapies for patients with symptoms of opioid-induced bowel dysfunctionChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesTreatment of opioid-induced gut dysfunctionThe effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Recent advances: palliative care.Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceBowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.Review article: the therapy of constipation.Overview and treatment of opioid-induced constipation.Recent advances in the use of opioids for cancer painManagement of opioid-induced gastrointestinal effects in patients receiving palliative care.The management of constipation in people with advanced cancer.Opioid receptors in the gastrointestinal tract.Anticipating and treating opioid-associated adverse effects.Treatment of failed back surgery syndrome in a forty-three-year-old man with high-dose oxycodone/naloxone.Constipation: opioid antagonists in people prescribed opioidsOpioids and the gut: pharmacology and current clinical experience.Improving opioid effectiveness: from ideas to evidence.Alvimopan, a selective peripherally acting mu-opioid antagonist.Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in miceDesign, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Ensuring pain relief for children at the end of life.New approaches to the treatment of opioid-induced constipation.Effectiveness of two opioid antagonists in treating opioid-induced constipation.Opioid-induced constipation: challenges and therapeutic opportunities.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Oxycodone for the treatment of postoperative pain.Opioid-induced bowel dysfunction: pathophysiology and management.Combined oral prolonged-release oxycodone and naloxone in chronic pain management.The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities
P2860
Q24243268-C1808882-E5D0-4E8A-A434-085D88EB73C6Q26745747-AD194BC3-BC3A-44B8-9D4A-2F6E6F545C68Q26765571-CD7C9F73-36F5-4167-A4A6-C6643597D3AFQ26777692-E478B46C-AB8C-4F2C-BFF1-F5399F20A672Q26995944-DA40321A-0B3B-4F1A-A8AC-5895A77D2272Q27010907-0317EE08-F9D2-4AC9-93E2-8924975C939EQ28083547-0A1A4E2A-2B78-4327-A56A-5643C6588570Q28284578-236F39CD-7214-41D4-A62F-63D4BE9FDAABQ30490602-CC53B2F9-C479-4969-BADE-3E8BB2E01C48Q33296232-00503607-A2E5-4022-B008-4C041AB0A7E5Q33520508-AF68DD91-8D25-466B-B31D-987550C97453Q33709851-AA2E2F4E-E3C9-448E-B2C4-4BABC15C0882Q33715430-6429970F-9E89-4533-8FE7-5DEDABE30117Q33801768-F2DC5FFC-9ABB-4BD8-A441-0B12EC647AE3Q33938740-EF027017-A50B-4CBE-A2C0-31FF43D2E216Q34170592-0104DAB8-5A7F-4481-B287-53DE8C1E2CDEQ34266216-C7B08563-67AC-480B-AF97-F92ADA9479D6Q34352001-C102A589-4CB2-4639-BF60-79E308557435Q34418203-8F99794C-A17B-4B32-BD0F-AA3FA2D2E41AQ34523889-ED6E2A66-F2A5-47FC-A90D-47C2633C82DAQ34793814-88FA1FCD-8409-4AD4-A3D8-3A1BBA9882BDQ35185222-9AB83AC8-FC47-4CBE-9D3F-05E4E6D0824BQ35194392-E03FFDC2-136D-4E5C-B2B0-23448CA5A48AQ35226014-80FDA90F-3285-435A-800A-0C25C58899D1Q35770714-8075DCF5-6510-4EC4-8D2B-4EB4CB22FC7AQ35860904-4BDB76E3-DC92-4CF2-A89A-A13C1B32C27FQ36057741-18C74C5E-775B-469E-932B-EDE62B026F9CQ36078760-730036BE-A79C-4AA3-BF55-CD3B9662F219Q36178704-517768F0-E829-43F2-A606-6E09BC02B62EQ36480105-272D1494-2E6A-4864-B8E8-37D3DF95535FQ36589067-44D338C5-88CA-4CDA-8EA9-FCBF324771CCQ37299608-1938B26A-DC7F-4B32-AB7D-EDCA10DECBE2Q37601903-667083A2-FB44-486F-9F3B-579E54F60E5DQ37846099-B5CB6209-1051-4CB5-B227-B3EFE2A4D17AQ37954521-9CA400B2-FE81-4D58-88F3-1D1C8C25CAF7Q37960501-72588F3E-5432-4063-B540-329C3E037E5FQ38004077-BAE2CF9E-100E-4A74-9DA8-70600738DC53Q38040843-55C9D4B6-4765-4E36-9898-2C573CDADC2BQ38065187-D5A3EADE-9D88-4DB8-AC06-D8352A039E61Q38116004-28ED15A3-84D9-4388-8A72-C1D6383C361C
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Oral naloxone reverses opioid-associated constipation.
@ast
Oral naloxone reverses opioid-associated constipation.
@en
type
label
Oral naloxone reverses opioid-associated constipation.
@ast
Oral naloxone reverses opioid-associated constipation.
@en
prefLabel
Oral naloxone reverses opioid-associated constipation.
@ast
Oral naloxone reverses opioid-associated constipation.
@en
P2093
P1433
P1476
Oral naloxone reverses opioid-associated constipation.
@en
P2093
P304
P356
10.1016/S0304-3959(99)00185-2
P407
P577
2000-01-01T00:00:00Z